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Malignant fibrous histiocytoma is a common form 
of soft-tissue sarcoma in adulthood [1]. Surgical 
management remains the cornerstone of therapy for 
soft tissue sarcomas. Unfortunately, approximately 
40% of patients with soft tissue sarcoma will develop 
local or distant disease recurrences [2], and systemic 
chemotherapy with palliative intent is conventionally 
used to treat the metastatic disease [3].
Targeted biological treatment with the use of tyrosine ki-
nase inhibitors (TKIs) entered medical oncology practice the 
last decade. The advances in understanding the molecular 
biology of many sarcomas have led to the development of 
new targeted treatment options. Imatinib is a small molecule 
inhibitor that blocks the aberrant tyrosine kinase activity 
of the BCR-ABL fusion oncoprotein, and it is the actual 
standard of care in the management of unresectable and 
metastatic gastrointestinal stromal tumors (GIST) [4, 5].
Sunitinib is an oral multitargeted tyrosine kinase 
inhibitor of vascular endothelial growth factor recep-
tor (VEGFR), platelet-derived growth factor receptor 
(PDGFR), c-Kit, and FLT-3 kinase, that has potent anti-
angiogenic and antitumour activities [6, 7]. Treatment 
with sunitinib is actually recommended in the manage-
ment of renal cancer [8, 9] and second line treatment 
of gastrointestinal stromal tumors [10].
Herein, we describe a case of metastatic fibrous his-
tiocytoma successfully treated with sunitinib. In July 2008, 
a 62 year-old man came at the ambulatory department 
for a second opinion for management of side effects of 
TKIs treatment. The patient reported he was treated with 
Sunitinib (50 mg once daily for four weeks followed by two 
weeks rest) and referred weight loss with a reduced ap-
petite, dermatologic lesions, symptoms of neuropathy and 
severe mucositis.  Clinical evaluation revealed hand and 
foot syndrome-grade 3, gingivitis-grade 2–3 and anemia. 
Full blood count showed macrocytic anemia, while the rest 
of the biochemical blood exams were normal.
Patient referred having renal cancer since Februa-
ry 2005 for which he had undergone a left kidney nephre-
ctomy in April 2005. He reported that the neoplastic mass 
was invading the small intestine, with no renal vessels 
invasion or regional lymph node involvement. After the 
operation, oncologists recommended adjuvant treatment 
with adriamycin and iphosphamide, which he refused. In 
June 2007, chest and upper abdominal CT scans revealed 
local relapse, metastases in both lungs and bone involve-
ment. Treatment with Sunitinib and bisphosphonates was 
initiated. Long lasting objective responses were observed 
in both bone and lung metastases and disease stabilization 
was observed in the regional relapse. In August 2008, the 
patient was still responding to treatment (Figure).
In general, renal cancer does not infiltrate the small 
intestine. Moreover, the absence of local lymphadenopa-
thy and blood vessel invasion, as well as the indication 
of adjuvant intravenous chemotherapy for renal cancer, 
indicated a diagnostic-therapeutic bias. Indeed, the 
referred diagnosis of renal cancer did not cope with 
patient’s disease report. Therefore, patient was asked 
to submit the nephrectomy pathology report on the fol-
lowing visit. A malignant fibrous histiocytoma, invading 
the lower pole of the left kidney, the perinephric adipose 
tissue and the small intestine was reported. No evidence 
of renal adenocarcinoma was found from patient’s 
medical-chart audit. Despite the diagnostic-therapeutic 
bias and the fact that, tyrosine kinase inhibitors are not 
recommended for the treatment of malignant fibrous 
histiocytoma, the patient is doing well, with a 13 months 
progression free interval.  Due to the patient’s clinical 
response, continuation of the treatment was decided. 
Sunitinib side effects were managed with dose reduction 
to 37.5 mg per day and administration of oral pyridoxine 
and benzydamine hydrochloride mouthwash.
At our knowledge, this case represents the third 
report presenting clinical beneficial effects of TKIs in 
the treatment of fibrous histiocytoma and the second 
one documenting the potential long term benefit of the 
treatment. Indeed, two previous studies including 13 and 
11 fibrous histiocytoma patients, respectively, evidenced 
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high percent of stable disease but no complete or partial 
responders [11, 16]. These reports represent an important 
cornerstone, to trigger and extend the research on the role 
of TKIs in the treatment of diffe rent types of sarcoma.
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Figure. Pulmonary metastases before treatment (a) and after 
treatment with tyrosine kinase inhibitors for 13 months (b). No-
table reduction in number and size of pulmonary metastases 
during the course of Sunitinib treatment was observed
As a matter of fact, the TKIs’ beneficial effects re-
ported in our patient should not surprise. TKIs are the 
treatment of choice for gastrointestinal stromal tumor in 
both 1st and 2nd line setting [10, 12]. Furthermore, there 
are few recent reports outlining the potential value of su-
nitinib and other multitargeted tyrosine kinase inhibitors, 
such as sorafenib and pazopanib, for treating subtypes of 
sarcomas other than fibrous histiocytoma [13–17]. More-
over, preclinical data evidenced that imatinib mesylate 
reduced tumor growth of fibrous histiocytoma cell lines 
expressing PDGFR and c-Kit [18]. Thereafter, the pos-
sibility that TKI may effectively work on patients affected 
by malignant fibrous histiocytoma is consistent.
Anyhow, despite the positive effects observed, we 
discourage deliberate administration of TKIs for treat-
ment of fibrous histiocytoma, until TKIs will be clearly 
indicated for the treatment of the disease. Thereafter, 
their use should be considered still investigatory and 
not tried out of strict research protocols.
Nevertheless, pour considering the limits of our report, 
it is only a retrospective case (identified by medical chart 
audit), characterized by TKIs administration out of a strict 
research protocol, we believe that, the observed good re-
sponse and long lasting beneficious effects should be taken 
into consideration. This case may be an important step 
for the treatment of these sarcomas. Extensive controlled 
research has to be conducted to confirm these findings.
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